AR039059A1 - Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios - Google Patents
Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediariosInfo
- Publication number
- AR039059A1 AR039059A1 ARP020102935A ARP020102935A AR039059A1 AR 039059 A1 AR039059 A1 AR 039059A1 AR P020102935 A ARP020102935 A AR P020102935A AR P020102935 A ARP020102935 A AR P020102935A AR 039059 A1 AR039059 A1 AR 039059A1
- Authority
- AR
- Argentina
- Prior art keywords
- compound
- group
- formula
- alkyl
- halogen atom
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title abstract 7
- 238000000034 method Methods 0.000 title abstract 2
- 239000008194 pharmaceutical composition Substances 0.000 title abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 5
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 abstract 4
- 125000006274 (C1-C3)alkoxy group Chemical group 0.000 abstract 4
- 125000006272 (C3-C7) cycloalkyl group Chemical group 0.000 abstract 4
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 abstract 4
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 abstract 3
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 abstract 2
- 208000024827 Alzheimer disease Diseases 0.000 abstract 2
- -1 methylenedioxy Chemical group 0.000 abstract 2
- 230000007170 pathology Effects 0.000 abstract 2
- 125000003386 piperidinyl group Chemical group 0.000 abstract 2
- 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 abstract 2
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 2
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 abstract 1
- 206010059245 Angiopathy Diseases 0.000 abstract 1
- MYMOFIZGZYHOMD-UHFFFAOYSA-N Dioxygen Chemical compound O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 abstract 1
- 201000010374 Down Syndrome Diseases 0.000 abstract 1
- 208000018737 Parkinson disease Diseases 0.000 abstract 1
- 206010039966 Senile dementia Diseases 0.000 abstract 1
- 239000002253 acid Substances 0.000 abstract 1
- 230000015572 biosynthetic process Effects 0.000 abstract 1
- 208000026106 cerebrovascular disease Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 125000004043 oxo group Chemical group O=* 0.000 abstract 1
- 229910052760 oxygen Inorganic materials 0.000 abstract 1
- 239000001301 oxygen Substances 0.000 abstract 1
- 108090000765 processed proteins & peptides Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 239000012453 solvate Substances 0.000 abstract 1
- 229910052717 sulfur Inorganic materials 0.000 abstract 1
- 125000004434 sulfur atom Chemical group 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/40—Unsubstituted amino or imino radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/42—Amino or imino radicals substituted by hydrocarbon or substituted hydrocarbon radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
- C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
- C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D277/38—Nitrogen atoms
- C07D277/44—Acylated amino or imino radicals
- C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- General Health & Medical Sciences (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Biomedical Technology (AREA)
- Public Health (AREA)
- Urology & Nephrology (AREA)
- Heart & Thoracic Surgery (AREA)
- Vascular Medicine (AREA)
- Cardiology (AREA)
- Psychology (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
Abstract
Compuesto derivado de acilaminotiazol que responde a la fórmula general (1): en la cual, n es igual a 0, 1, 2 ó 3; X representa un átomo de oxígeno o de azufre; R1 representa, independientemente entre sí cuando n = 2 ó 3, un átomo de halógeno, un hidroxi, un alquilo C1-3, un alcoxi C1-3, un trifluorometilo, un trifluorometiloxi o un metilendioxi; R2 representa un grupo alquilo C1-6 eventualmente sustituido por un grupo cicloalquilo C3-7, un fenilo, un grupo alcoxi C1-3, un hidroxi o un átomo de halógeno; un grupo cicloalquilo C3-7, piperidinilo o fenilo; los grupos cicloalquilo C3-7, piperidinilo y fenilo están eventualmente sustituidos por uno o varios grupos alquilo C1-3, alcoxi C1-3, un hidroxi o un átomo de halógeno; R3 representa un átomo de hidrógeno o un grupo alquilo C1-6 eventualmente sustituido por un grupo cicloalquilo C3-7; R4 representa un átomo de hidrógeno o un grupo alquilo C1-4; R5 y R5' representan , independientemente entre sí, un átomo de hidrógeno, un hidroxi, un átomo de halógeno, un grupo alquilo C1-3; o R5 y R5' forman juntos y un grupo oxo; y R6 representa un átomo de hidrógeno, un átomo de halógeno, un alquilo C1-3, un alcoxi C1-3, un trifluorometilo o un trifluorometoxi; en estado de base, de sal de adición con un ácido, de hidrato o de solvato. Su utilización, procedimientos para prepararlo, composición farmacéutica que lo comprende, Compuesto de fórmula (2) en la cual X, R2 y R4 son tal como se han definido anteriormente y Pg representa una difenilcetona imina, compuesto de fórmula (3) en la cual X, R2 y R4 son tal como se han definido anteriormente, y compuesto de fórmula (4) en la cual X, R2, R3 y R4 son tal como han sido definidos anteriormente. El compuesto de fórmula (1) es útil en el tratamiento de patologías en las cuales un inhibidor de la formación del péptido b-amiloide (b-A4) aporta un beneficio terapéutico. Esas patologías son particularmente, la demencia senil, la enfermedad de Alzheimer, el síndrome de Down, la enfermedad de Parkinson, la angiopatía amiloide y los desórdenes cerebrovasculares.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| FR0110504 | 2001-08-06 | ||
| FR0207222A FR2840899B1 (fr) | 2002-06-12 | 2002-06-12 | Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR039059A1 true AR039059A1 (es) | 2005-02-09 |
Family
ID=26213132
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP020102935A AR039059A1 (es) | 2001-08-06 | 2002-08-02 | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US7288659B2 (es) |
| EP (1) | EP1417189B1 (es) |
| JP (1) | JP2005500370A (es) |
| AR (1) | AR039059A1 (es) |
| AT (1) | ATE312828T1 (es) |
| DE (1) | DE60208044T2 (es) |
| DK (1) | DK1417189T3 (es) |
| ES (1) | ES2254773T3 (es) |
| TW (1) | TWI318974B (es) |
| WO (1) | WO2003014095A1 (es) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI314928B (en) | 2002-02-28 | 2009-09-21 | Novartis A | 5-phenylthiazole derivatives and use as pi3 kinase inhibitors |
| CA2501803A1 (en) * | 2002-10-09 | 2004-04-22 | Pfizer Products Inc. | Thiazole compounds for the treatment of neurodegenerative disorders |
| FR2850380B1 (fr) * | 2003-01-23 | 2006-07-07 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur utilisation en therapeutique |
| CA2524511A1 (en) * | 2003-05-12 | 2004-11-18 | Pfizer Products Inc. | Isoxazole and isothiazole compounds for the treatment of neurodegenerative disorders |
| EP1653952A4 (en) * | 2003-08-06 | 2007-04-04 | Pfizer Prod Inc | OXAZOLE COMPOUNDS FOR THE TREATMENT OF NEURODEEGENERATIVE DISORDER |
| FR2865206B1 (fr) * | 2004-01-16 | 2009-02-06 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| AU2005209442B2 (en) * | 2004-01-16 | 2011-03-31 | Sanofi-Aventis | Acylaminothiazole derivatives, preparation method thereof and use of same in therapeutics |
| FR2873374B1 (fr) * | 2004-07-22 | 2006-10-20 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| FR2865207B1 (fr) * | 2004-01-16 | 2008-10-17 | Sanofi Synthelabo | Derives d'acylaminothiazole, leur preparation et leur application en therapeutique |
| PT1709018E (pt) * | 2004-01-16 | 2011-10-24 | Sanofi Sa | Derivados de acilaminotiazole e sua aplicação como inibidores |
| US7232820B2 (en) * | 2004-04-01 | 2007-06-19 | Pfizer Inc | Thiadiazole-amine compounds for the treatment of neurodegenerative disorders |
| US7220865B2 (en) * | 2004-04-01 | 2007-05-22 | Pfizer Inc | Isoxazole-and isothiazole-amine compounds for the treatment of neurodegenerative disorders |
| AU2007207743B2 (en) * | 2006-01-18 | 2010-07-08 | Amgen Inc. | Thiazole compounds as protein kinase B (PKB) inhibitors |
| CA2692713A1 (en) | 2007-07-17 | 2009-01-22 | Amgen Inc. | Heterocyclic modulators of pkb |
| AU2008276512A1 (en) * | 2007-07-17 | 2009-01-22 | Amgen Inc. | Thiadiazole modulators of PKB |
| EP3436448A1 (en) * | 2016-03-31 | 2019-02-06 | Merck Patent GmbH | Compounds for the inhibition of cyclophilins and uses thereof |
| ES2958118T3 (es) | 2018-01-18 | 2024-02-01 | Daiichi Sankyo Co Ltd | Derivado de dihidroindolizinona |
| AU2020309946A1 (en) | 2019-07-08 | 2022-03-03 | Daiichi Sankyo Company, Limited | Method for producing insulin-producing cell using dihydroindolizinone derivatives |
Family Cites Families (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AR016751A1 (es) | 1996-11-22 | 2001-08-01 | Athena Neurosciences Inc | Metodo para inhibir la liberacion del peptido beta-amiloide en una celula, composicion farmaceutica y compuestos utiles en dicho metodo |
| TR199901603T2 (xx) | 1996-11-22 | 2000-02-21 | Elan Pharmaceuticals, Inc. | N-(aril/heteroaril/alkilasetil) amino asit amidler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler. |
| TR199901343T2 (xx) * | 1996-12-23 | 1999-09-21 | Elan Pharmaceuticals, Inc. | Sikloalkil, laktam, lakton ve ilgili bile�ikler, bunlar� i�eren farmas�tik bile�imler ve b�yle bile�ikler kullan�larak �-amiloid peptidinin sal�nmas�n� ve/veya sentezini inhibe etmek i�in y�ntemler. |
| HRP980093A2 (en) | 1997-02-28 | 1998-12-31 | Lilly Co Eli | Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting "beta"-amyloid peptide release and/or its synthesis by use of such compounds |
| AU6278099A (en) * | 1998-09-30 | 2000-04-17 | Elan Pharmaceuticals, Inc. | Biological reagents and methods for determining the mechanism in the generation of beta-amyloid peptide |
| WO2000024392A1 (fr) | 1998-10-26 | 2000-05-04 | Sumitomo Pharmaceuticals Company, Limited | Inhibiteur de la formation de beta-amyloide |
-
2002
- 2002-08-02 AR ARP020102935A patent/AR039059A1/es active IP Right Grant
- 2002-08-05 JP JP2003519045A patent/JP2005500370A/ja active Pending
- 2002-08-05 US US10/485,837 patent/US7288659B2/en not_active Expired - Lifetime
- 2002-08-05 WO PCT/FR2002/002802 patent/WO2003014095A1/fr active IP Right Grant
- 2002-08-05 DK DK02794623T patent/DK1417189T3/da active
- 2002-08-05 AT AT02794623T patent/ATE312828T1/de active
- 2002-08-05 EP EP02794623A patent/EP1417189B1/fr not_active Expired - Lifetime
- 2002-08-05 ES ES02794623T patent/ES2254773T3/es not_active Expired - Lifetime
- 2002-08-05 DE DE60208044T patent/DE60208044T2/de not_active Expired - Lifetime
- 2002-08-05 TW TW091117569A patent/TWI318974B/zh not_active IP Right Cessation
-
2007
- 2007-09-20 US US11/858,454 patent/US20080058380A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20080058380A1 (en) | 2008-03-06 |
| DE60208044T2 (de) | 2006-08-17 |
| EP1417189A1 (fr) | 2004-05-12 |
| DK1417189T3 (da) | 2006-05-08 |
| ATE312828T1 (de) | 2005-12-15 |
| JP2005500370A (ja) | 2005-01-06 |
| US20040171643A1 (en) | 2004-09-02 |
| TWI318974B (en) | 2010-01-01 |
| DE60208044D1 (de) | 2006-01-19 |
| ES2254773T3 (es) | 2006-06-16 |
| EP1417189B1 (fr) | 2005-12-14 |
| WO2003014095A1 (fr) | 2003-02-20 |
| US7288659B2 (en) | 2007-10-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR039059A1 (es) | Compuesto derivado de acilaminotiazol, su utilizacion, procedimientos para prepararlo, composicion farmaceutica que lo comprende, y compuestos intermediarios | |
| AR061371A1 (es) | Amino - imidazolonas y su uso como medicamento para la enfermedad de alzheimer y otras enfermedades neurodegenerativas. | |
| TNSN07471A1 (en) | Novel 2,4 - dianilinopyrimidine derivatives, the preparation thereof, their use as medicaments, pharmaceutical compositions and, in particular, as ikk inhibitors | |
| NO20063761L (no) | Sulfonamidderivater for behandling av sykdommer | |
| AR086552A1 (es) | 4-aril-n-fenil-1,3,5-triazin-2-aminas que contienen un grupo sulfoximina y composicion farmaceutica | |
| NO20090029L (no) | Pyrrolopyrimidiner for farmasoytiske formuleringer | |
| AR062680A1 (es) | Sintesis de 2-(piridin-2-ilamino) pirido [2,3-d] pirimidin-7-onas | |
| AR041566A1 (es) | Derivados de indol utiles para el tratamiento de enfermedades | |
| AR052938A1 (es) | Compuestos de n-sulfonilaminofeniletil-2-fenoxiacetamida sustituidos, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el receptor vr1 | |
| CO6280485A2 (es) | Inhibidores de 11-beta hidroxiesteroide deshidrogenasa tipo i de triazolopiridina | |
| RU2009109678A (ru) | Аллостерические модуляторы метаботропных глутаматных рецепторов | |
| AR068055A1 (es) | Derivados de 6-triazolopiridacina-sulfanil benzotiazol y bencimidazol su procedimiento de preparacion su aplicacion como medicamentos composiciones farmaceuticas y su utilizacion principalmente como inhibidores de met | |
| AR041459A1 (es) | Derivados de indazolcarboxamidas su preparacion y su utilizacion en terapeutica | |
| AR035617A1 (es) | Compuestos derivados de fenetanolamina, combinaciones y formulaciones farmaceuticas de los mismos, proceso para su preparacion, su uso en la preparacion de medicamentos para el tratamiento o profilaxis de una condicion clinica para la cual se indica un agonista beta2 adreno-receptor e intermediarios | |
| AR055613A1 (es) | Formas cristalinas delta y epsilon de mesilato de imatinib | |
| CO5631432A2 (es) | Derivados de n-[fenil(piepidin-2-il)metil]benzamida, su preparacion y su aplicacion en terapeutica | |
| ATE540037T1 (de) | Triazolopyridine als phosphodiesterasehemmer zur behandlung von hautkrankheiten | |
| AR072819A1 (es) | Derivados de triazolo[4,3-a]piridina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
| AR066107A1 (es) | Derivados de triazolopiridin - carboxamidas y triazolopirimidin-carboxamidas, su preparacion y su aplicacion en terapeutica como inhibidores de la enzimamonoacil glicerol lipasa y composiciones qu los contienen. | |
| EA200601223A1 (ru) | Производные сульфонамида для лечения заболеваний | |
| AR072820A1 (es) | Derivados de imidazo[1,2-a]pirimidina,procedimiento de preparacion,intermediarios de dicho proceso,composiciones farmaceuticas que los comprenden y uso de los mismos, como inhibidores de la proteinquinasa met,para el tratamiento de canceres,psoriasis,enfermedades del sistema nervioso central y otras | |
| AR079250A1 (es) | Derivados de pirazolo[1,5-a]piridina utiles en el tratamiento de enfermedades del snc y canceres, composiciones farmaceuticas que los contienen e intermediario de sintesis. | |
| AR070485A1 (es) | Compuestos derivados de azetidinas, su preparacion y su aplicacion en terapeutica | |
| AR077447A1 (es) | Compuestos inhibidores de beta-secretasa, utiles para el tratamiento de enfermedades neurodegenerativas | |
| AR073043A1 (es) | Compuestos de azetidinas polisustituidos, composiciones farmaceuticas que los contienen, metodo de preparacion y uso de los mismos en el tratamiento de enfermedades respiratorias, metabolicas y del sistema nervioso central, entre otras. |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant, registration |